X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with Dishman Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs DISHMAN PHARMA - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA DISHMAN PHARMA GSK PHARMA/
DISHMAN PHARMA
 
P/E (TTM) x 61.0 25.1 243.0% View Chart
P/BV x 11.4 3.3 340.5% View Chart
Dividend Yield % 2.5 0.7 380.7%  

Financials

 GSK PHARMA   DISHMAN PHARMA
EQUITY SHARE DATA
    GSK PHARMA
Mar-18
DISHMAN PHARMA
Mar-16
GSK PHARMA/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs2,760374 737.2%   
Low Rs2,040129 1,582.6%   
Sales per share (Unadj.) Rs339.0197.8 171.4%  
Earnings per share (Unadj.) Rs41.421.2 195.3%  
Cash flow per share (Unadj.) Rs45.934.7 132.2%  
Dividends per share (Unadj.) Rs35.002.00 1,750.0%  
Dividend yield (eoy) %1.50.8 183.5%  
Book value per share (Unadj.) Rs242.9179.9 135.0%  
Shares outstanding (eoy) m84.7080.69 105.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.11.3 556.4%   
Avg P/E ratio x57.911.9 488.3%  
P/CF ratio (eoy) x52.37.2 721.4%  
Price / Book Value ratio x9.91.4 706.3%  
Dividend payout %84.59.4 896.0%   
Avg Mkt Cap Rs m203,28020,306 1,001.1%   
No. of employees `000NA0.8 0.0%   
Total wages/salary Rs m5,2345,355 97.7%   
Avg. sales/employee Rs ThNM19,252.7-  
Avg. wages/employee Rs ThNM6,459.5-  
Avg. net profit/employee Rs ThNM2,064.1-  
INCOME DATA
Net Sales Rs m28,71515,961 179.9%  
Other income Rs m545265 205.5%   
Total revenues Rs m29,26016,226 180.3%   
Gross profit Rs m5,0594,103 123.3%  
Depreciation Rs m3801,091 34.8%   
Interest Rs m2944 0.2%   
Profit before tax Rs m5,2222,334 223.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m1780-   
Tax Rs m1,892624 303.4%   
Profit after tax Rs m3,5081,711 205.0%  
Gross profit margin %17.625.7 68.5%  
Effective tax rate %36.226.7 135.6%   
Net profit margin %12.210.7 114.0%  
BALANCE SHEET DATA
Current assets Rs m21,81511,018 198.0%   
Current liabilities Rs m15,9999,517 168.1%   
Net working cap to sales %20.39.4 215.4%  
Current ratio x1.41.2 117.8%  
Inventory Days Days64110 57.5%  
Debtors Days Days1935 53.6%  
Net fixed assets Rs m12,47516,304 76.5%   
Share capital Rs m847161 524.8%   
"Free" reserves Rs m19,72612,907 152.8%   
Net worth Rs m20,57314,516 141.7%   
Long term debt Rs m64,189 0.1%   
Total assets Rs m39,47529,805 132.4%  
Interest coverage x2,612.03.5 75,252.4%   
Debt to equity ratio x00.3 0.1%  
Sales to assets ratio x0.70.5 135.8%   
Return on assets %8.98.9 99.8%  
Return on equity %17.111.8 144.6%  
Return on capital %26.217.5 149.7%  
Exports to sales %024.8 0.0%   
Imports to sales %03.7 0.0%   
Exports (fob) Rs mNA3,956 0.0%   
Imports (cif) Rs mNA596 0.0%   
Fx inflow Rs m5644,952 11.4%   
Fx outflow Rs m7,429697 1,066.2%   
Net fx Rs m-6,8654,255 -161.4%   
CASH FLOW
From Operations Rs m4,7282,786 169.7%  
From Investments Rs m-1,042-1,529 68.1%  
From Financial Activity Rs m-3,066-941 325.8%  
Net Cashflow Rs m620316 195.9%  

Share Holding

Indian Promoters % 0.0 61.4 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 3.7 275.7%  
FIIs % 23.8 12.7 187.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 22.1 69.7%  
Shareholders   102,036 46,261 220.6%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   STERLING BIOTECH  SANOFI INDIA  ALEMBIC PHARMA  ORCHID PHARMA LTD  PFIZER  

Compare GSK PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Flat; Capital Goods & Banking Stocks Lag(09:30 am)

Asian stock markets are lower today as Chinese and Hong Kong shares fall. The Shanghai Composite is off 0.5% while the Hang Seng is down 1.2%.

Related Views on News

GSK PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 22.7% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 22.7% YoY). Sales on the other hand came in at Rs 8 bn (down 2.4% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 235.3% (Quarterly Result Update)

Jul 26, 2018 | Updated on Jul 26, 2018

For the quarter ended June 2018, GSK PHARMA has posted a net profit of Rs 886 m (up 235.3% YoY). Sales on the other hand came in at Rs 7 bn (up 21.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

3 Big Money Makers to Round Out Your 2018 Portfolio(Profit Hunter)

Oct 31, 2018

The market is offering many strong opportunities in the small cap space right now. Don't miss out. This is the time to get rich.

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are You Among The 35% Parents Who Will Not Be Able To Finance Their Child's Future?(Outside View)

Nov 1, 2018

PersonalFN explains the importance of being prepared for your child's future.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Nov 13, 2018 10:45 AM

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA 8-QTR ANALYSIS

COMPARE GSK PHARMA WITH

MARKET STATS